Search

Nuclear energy is an important alternative energy source. However, construction of nuclear power plants (NPPs) requires the consideration of environmental, economic, socioeconomic, health, and safety factors since using such an energy source involves some risks during the operation lifetime of a NPP. Accordingly, the selection of the most suitable site for a NPP yields a multicriteria decision making (MCDM) problem. Natural hazards, health hazards, environmental conditions, population density, and the availability of water resources are among the main factors that should be considered. To demonstrate the application of the proposed methodology, two previously identified NPP sites in Turkey, specifically, Mersin-Akkuyu and Sinop-Abalı, are compared utilizing the multicriteria utility functions. In the comparison of these two sites, seismic hazard, tsunami hazard; extreme wind hazard; distance to facilities; population density; proximity to the city center; existence of forests, natural parks, nature conservation areas, and natural monuments; biodiversity; and immovable cultural heritage have been identified as the most important critical criteria and are evaluated concerning the utility functions developed for each criterion. The optimal site is selected within the framework of the MCDM rules, and is recommended as the output of the study. [ABSTRACT FROM AUTHOR]

Non-normal innovations in autoregression models frequently occur in practice. In this situation, least squares (LS) estimators are known to be inefficient and non-robust, and maximum likelihood (ML) estimators need to be solved numerically, which becomes a daunting task. In the literature, the modified maximum likelihood (MML) estimation technique has been proposed to obtain the estimators of model parameters. While an explicit solution can be found via this method, the requirement of knowing the shape parameter becomes a drawback, especially in machine learning. In this study, we use the adaptive modified maximum likelihood (AMML) methodology, which combines the MML with Huber's M-estimation so that this assumption is relaxed. The performance of the method in terms of efficiency and robustness is analyzed via simulation and compared to LS, MML and ML estimates that are obtained numerically via the Expectation Conditional Maximization (ECM) algorithm. Test statistics are proposed for the crucial parameters of the model. The results show that the AMML estimators are preferable in most of the settings according to the mean squared error (MSE) criterion and the test statistics based on AMML method are more robust than the others. Furthermore, both real life and synthetic data examples are given. [ABSTRACT FROM AUTHOR]

Summary: The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions. Click here for the corresponding questions to this CME article. [ABSTRACT FROM AUTHOR]

Summary: The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions. Click here for the corresponding questions to this CME article. [ABSTRACT FROM AUTHOR]

Summary: The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID‐19, chilblain‐like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children, for both COVID‐19 and any other pre‐existing conditions. Click here for the corresponding questions to this CME article. [ABSTRACT FROM AUTHOR]

Modified maximum likelihood estimators of the parameters in a second order polynomial regression model are derived. They are shown to be considerably more efiicient and robust than the commonly used least squares estimators. Real life examples are given. [ABSTRACT FROM AUTHOR]